MedPath

Mycophenolic acid

Generic Name
Mycophenolic acid
Brand Names
Myfortic
Drug Type
Small Molecule
Chemical Formula
C17H20O6
CAS Number
24280-93-1
Unique Ingredient Identifier
HU9DX48N0T
Background

Mycophenolic acid is a potent immunosuppressant agent that inhibits de novo purine biosynthesis. It was derived from Penicillium stoloniferum, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative azathioprine due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity. Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until it reaches the small intestine. Mycophenolate mofetil, a prodrug of mycophenolic acid, is also prescribed to transplant recipients to prevent organ rejection.

Indication

Mycophenolic acid is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. Mycophenolic acid is used in combination with cyclosporine and corticosteroids.

Associated Conditions
Kidney Transplant Rejection

Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen

Phase 4
Conditions
Kidney Transplant Recipients
Interventions
First Posted Date
2020-06-24
Last Posted Date
2022-05-27
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Target Recruit Count
300
Registration Number
NCT04444843
Locations
🇨🇳

First Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shaanxi, China

Comparison between2 Drugs in Lupus Nephritis

Phase 4
Completed
Conditions
Lupus Nephritis
Interventions
Drug: cyclo phosphamide
First Posted Date
2020-06-11
Last Posted Date
2022-06-21
Lead Sponsor
Al-Azhar University
Target Recruit Count
40
Registration Number
NCT04424602
Locations
🇪🇬

ALAzhar university, Cairo, Egypt

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Phase 1
Recruiting
Conditions
Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory Chronic Myelomonocytic Leukemia
Refractory Mixed Phenotype Acute Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome
Refractory Acute Leukemia of Ambiguous Lineage
Refractory Acute Undifferentiated Leukemia
Interventions
Procedure: Hematopoietic Cell Transplantation
Radiation: Total-Body Irradiation
Procedure: Multigated Acquisition Scan
Procedure: Echocardiography
Procedure: X-Ray Imaging
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection
First Posted Date
2020-05-05
Last Posted Date
2025-02-20
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
120
Registration Number
NCT04375631
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Phase 2
Recruiting
Conditions
Autoimmune Lymphoproliferative
Common Variable Immunodeficiency
Immune System Diseases
Primary T-cell Immunodeficiency Disorders
Lymphoproliferative Disorders
Interventions
First Posted Date
2020-04-09
Last Posted Date
2025-04-15
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
66
Registration Number
NCT04339777
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Dose Escalation Study in de Novo Renal Transplantation

Phase 2
Completed
Conditions
Kidney Transplantation
Interventions
First Posted Date
2020-03-17
Last Posted Date
2025-02-27
Lead Sponsor
ITB-Med LLC
Target Recruit Count
13
Registration Number
NCT04311632
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Kansas University Medical Center, Kansas City, Kansas, United States

and more 1 locations

Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects

Phase 4
Active, not recruiting
Conditions
Kidney Transplant; Complications
Immune Suppression
Interventions
First Posted Date
2019-12-20
Last Posted Date
2024-04-04
Lead Sponsor
Oslo University Hospital
Target Recruit Count
100
Registration Number
NCT04207177
Locations
🇳🇴

Oslo University Hospital, Oslo, Norway

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Phase 2
Recruiting
Conditions
Acute Leukemia
Acute Lymphoblastic Leukemia
Anaplastic Large Cell Lymphoma
Acute Myeloid Leukemia
Adult Diffuse Large Cell Lymphoma
Lymphoplasmacytic Lymphoma
Mantle Cell Lymphoma
Mixed Phenotype Acute Leukemia
Myelodysplastic Syndrome
Prolymphocytic Leukemia
Interventions
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Radiation: Total-Body Irradiation
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Echocardiography
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
First Posted Date
2019-12-12
Last Posted Date
2025-01-14
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
60
Registration Number
NCT04195633
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study

First Posted Date
2019-12-02
Last Posted Date
2022-08-18
Lead Sponsor
Tang-Du Hospital
Target Recruit Count
200
Registration Number
NCT04182984
Locations
🇨🇳

Tangdu Hospotal, Xi'an, Shaanxi, China

Immunosuppression After Repeat Keratoplasty

Phase 2
Conditions
Keratopathy
Interventions
Drug: prescribe topical 0.03 % tacrolimus
First Posted Date
2019-11-01
Last Posted Date
2019-11-01
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Target Recruit Count
58
Registration Number
NCT04147390
Locations
🇮🇷

Ophthalmic Research Center, Tehran, Iran, Islamic Republic of

Treg Modulation With CD28 and IL-6 Receptor Antagonists

Phase 1
Completed
Conditions
Living-Donor Kidney Transplant
Kidney Transplant Recipients
Interventions
First Posted Date
2019-08-26
Last Posted Date
2024-10-09
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
24
Registration Number
NCT04066114
Locations
🇺🇸

Cleveland Clinic Foundation: Transplantation, Cleveland, Ohio, United States

🇺🇸

University of California San Francisco School of Medicine: Transplantation, San Francisco, California, United States

🇺🇸

University of Alabama School of Medicine: Transplantation, Birmingham, Alabama, United States

and more 4 locations
© Copyright 2025. All Rights Reserved by MedPath